{"entity":{"id":"nct06205706","kind":"trial","name":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by BioInvent International AB, active and no longer recruiting.","summary":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06205706 by BioInvent International AB, with 35 participants enrolled, started 2023-12-04 and due to reach its primary completion in 2027-07-14. Interventions recorded: BI-1910, Pembrolizumab. Conditions listed: Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06205706","url":"https://clinicaltrials.gov/study/NCT06205706"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["bioinvent-international"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06205706","phase":"1/2","setting":"Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","sponsor":"BioInvent International AB","enrolled":35,"outcomes":[]},"route":"/trials/nct06205706/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/"}]}}